Last reviewed · How we verify

NCT06431360

Effect of Strontium-90 Brachytherapy Combined With Hyperthermia in the Treatment of Keloid

Recruiting now NA Last updated 28 May 2024
What this trial tests

NA trial testing hyperthermia in Keloid in 80 participants. Currently enrolling.

Timeline
14 May 2024
Primary endpoint
31 May 2025
30 June 2025

Quick facts

Lead sponsorNanjing First Hospital, Nanjing Medical University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment80
Start date14 May 2024
Primary completion31 May 2025
Estimated completion30 June 2025
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 16 to 75, any sex, with Keloid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Keloid patients were randomized into the experimental and control groups. Experimental group: Strontium-90 (Sr-90) brachytherapy followed by hyperthermia. Control group: Sr-90 brachytherapy alone .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Current State of Clinical Trials for Keloid Management: An Analysis of Trials Registered on ClinicalTrials.gov.
    Park S, Li D, Guo L, Xu X. · · 2026 · PMID 42077711 · DOI 10.7759/cureus.106243

Verify or expand the search:

Other trials of hyperthermia

Trials testing the same drug.

Other recruiting trials for Keloid

Currently open trials in the same condition.

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06431360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing